|
Gene: MUS81 |
Gene summary for MUS81 |
Gene summary. |
Gene information | Species | Human | Gene symbol | MUS81 | Gene ID | 80198 |
Gene name | MUS81 structure-specific endonuclease subunit | |
Gene Alias | SLX3 | |
Cytomap | 11q13.1 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q53ES5 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
80198 | MUS81 | LZE20T | Human | Esophagus | ESCC | 3.82e-06 | 2.38e-01 | 0.0662 |
80198 | MUS81 | LZE24T | Human | Esophagus | ESCC | 1.86e-14 | 4.59e-01 | 0.0596 |
80198 | MUS81 | P1T-E | Human | Esophagus | ESCC | 2.49e-05 | 3.61e-01 | 0.0875 |
80198 | MUS81 | P2T-E | Human | Esophagus | ESCC | 1.42e-17 | 3.20e-01 | 0.1177 |
80198 | MUS81 | P4T-E | Human | Esophagus | ESCC | 6.85e-21 | 5.31e-01 | 0.1323 |
80198 | MUS81 | P5T-E | Human | Esophagus | ESCC | 3.47e-13 | 3.66e-01 | 0.1327 |
80198 | MUS81 | P8T-E | Human | Esophagus | ESCC | 3.96e-15 | 2.61e-01 | 0.0889 |
80198 | MUS81 | P9T-E | Human | Esophagus | ESCC | 2.53e-06 | 1.61e-01 | 0.1131 |
80198 | MUS81 | P10T-E | Human | Esophagus | ESCC | 4.37e-13 | 2.08e-01 | 0.116 |
80198 | MUS81 | P11T-E | Human | Esophagus | ESCC | 2.09e-07 | 4.85e-01 | 0.1426 |
80198 | MUS81 | P12T-E | Human | Esophagus | ESCC | 1.03e-11 | 3.43e-01 | 0.1122 |
80198 | MUS81 | P15T-E | Human | Esophagus | ESCC | 1.11e-14 | 3.85e-01 | 0.1149 |
80198 | MUS81 | P16T-E | Human | Esophagus | ESCC | 6.23e-18 | 4.36e-01 | 0.1153 |
80198 | MUS81 | P17T-E | Human | Esophagus | ESCC | 3.06e-05 | 3.33e-01 | 0.1278 |
80198 | MUS81 | P20T-E | Human | Esophagus | ESCC | 3.86e-09 | 2.26e-01 | 0.1124 |
80198 | MUS81 | P21T-E | Human | Esophagus | ESCC | 8.66e-18 | 2.32e-01 | 0.1617 |
80198 | MUS81 | P22T-E | Human | Esophagus | ESCC | 2.79e-12 | 1.44e-01 | 0.1236 |
80198 | MUS81 | P23T-E | Human | Esophagus | ESCC | 1.92e-20 | 5.17e-01 | 0.108 |
80198 | MUS81 | P24T-E | Human | Esophagus | ESCC | 8.59e-11 | 2.58e-01 | 0.1287 |
80198 | MUS81 | P26T-E | Human | Esophagus | ESCC | 4.14e-11 | 2.04e-01 | 0.1276 |
Page: 1 2 3 4 5 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000705911 | Esophagus | ESCC | chromosome segregation | 238/8552 | 346/18723 | 1.72e-18 | 1.82e-16 | 238 |
GO:0034655110 | Esophagus | ESCC | nucleobase-containing compound catabolic process | 272/8552 | 407/18723 | 2.92e-18 | 2.90e-16 | 272 |
GO:000734615 | Esophagus | ESCC | regulation of mitotic cell cycle | 293/8552 | 457/18723 | 8.00e-16 | 5.64e-14 | 293 |
GO:004670018 | Esophagus | ESCC | heterocycle catabolic process | 286/8552 | 445/18723 | 1.12e-15 | 7.47e-14 | 286 |
GO:004427019 | Esophagus | ESCC | cellular nitrogen compound catabolic process | 288/8552 | 451/18723 | 3.03e-15 | 1.79e-13 | 288 |
GO:001943918 | Esophagus | ESCC | aromatic compound catabolic process | 295/8552 | 467/18723 | 1.09e-14 | 5.98e-13 | 295 |
GO:190136118 | Esophagus | ESCC | organic cyclic compound catabolic process | 307/8552 | 495/18723 | 9.99e-14 | 4.80e-12 | 307 |
GO:00482853 | Esophagus | ESCC | organelle fission | 301/8552 | 488/18723 | 4.64e-13 | 2.12e-11 | 301 |
GO:00988133 | Esophagus | ESCC | nuclear chromosome segregation | 187/8552 | 281/18723 | 1.00e-12 | 4.36e-11 | 187 |
GO:00002802 | Esophagus | ESCC | nuclear division | 270/8552 | 439/18723 | 1.17e-11 | 4.24e-10 | 270 |
GO:190198713 | Esophagus | ESCC | regulation of cell cycle phase transition | 242/8552 | 390/18723 | 3.86e-11 | 1.26e-09 | 242 |
GO:00457865 | Esophagus | ESCC | negative regulation of cell cycle | 236/8552 | 385/18723 | 3.62e-10 | 9.93e-09 | 236 |
GO:00000754 | Esophagus | ESCC | cell cycle checkpoint | 117/8552 | 169/18723 | 4.47e-10 | 1.17e-08 | 117 |
GO:004277014 | Esophagus | ESCC | signal transduction in response to DNA damage | 117/8552 | 172/18723 | 2.38e-09 | 5.32e-08 | 117 |
GO:00070934 | Esophagus | ESCC | mitotic cell cycle checkpoint | 90/8552 | 129/18723 | 2.49e-08 | 4.69e-07 | 90 |
GO:00903053 | Esophagus | ESCC | nucleic acid phosphodiester bond hydrolysis | 163/8552 | 261/18723 | 3.07e-08 | 5.73e-07 | 163 |
GO:00109484 | Esophagus | ESCC | negative regulation of cell cycle process | 177/8552 | 294/18723 | 3.26e-07 | 4.59e-06 | 177 |
GO:00315705 | Esophagus | ESCC | DNA integrity checkpoint | 83/8552 | 123/18723 | 8.17e-07 | 1.06e-05 | 83 |
GO:00000775 | Esophagus | ESCC | DNA damage checkpoint | 78/8552 | 115/18723 | 1.27e-06 | 1.56e-05 | 78 |
GO:19019883 | Esophagus | ESCC | negative regulation of cell cycle phase transition | 151/8552 | 249/18723 | 1.28e-06 | 1.57e-05 | 151 |
Page: 1 2 3 4 5 6 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MUS81 | SNV | Missense_Mutation | novel | c.1247C>T | p.Thr416Met | p.T416M | Q96NY9 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AC-A2FO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | chemo | CR |
MUS81 | SNV | Missense_Mutation | rs753119410 | c.1348N>T | p.Leu450Phe | p.L450F | Q96NY9 | protein_coding | tolerated(0.18) | benign(0.05) | TCGA-AC-A2QI-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cytoxan | CR |
MUS81 | SNV | Missense_Mutation | c.1187N>T | p.Gly396Val | p.G396V | Q96NY9 | protein_coding | deleterious(0) | probably_damaging(0.973) | TCGA-E2-A1BC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD | |
MUS81 | SNV | Missense_Mutation | rs753119410 | c.1348C>T | p.Leu450Phe | p.L450F | Q96NY9 | protein_coding | tolerated(0.18) | benign(0.05) | TCGA-GM-A3NY-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
MUS81 | SNV | Missense_Mutation | rs754849594 | c.1201N>T | p.Arg401Cys | p.R401C | Q96NY9 | protein_coding | deleterious(0.01) | possibly_damaging(0.891) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
MUS81 | SNV | Missense_Mutation | rs753816989 | c.463C>T | p.His155Tyr | p.H155Y | Q96NY9 | protein_coding | tolerated(1) | benign(0.055) | TCGA-JW-A5VI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | topotecan | PD |
MUS81 | SNV | Missense_Mutation | c.1417N>A | p.Glu473Lys | p.E473K | Q96NY9 | protein_coding | deleterious(0) | benign(0.407) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
MUS81 | SNV | Missense_Mutation | rs768086876 | c.1448N>A | p.Arg483His | p.R483H | Q96NY9 | protein_coding | tolerated(0.28) | benign(0) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
MUS81 | SNV | Missense_Mutation | novel | c.1282N>A | p.Leu428Ile | p.L428I | Q96NY9 | protein_coding | deleterious(0.04) | possibly_damaging(0.712) | TCGA-AA-3877-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MUS81 | SNV | Missense_Mutation | rs768086876 | c.1448N>A | p.Arg483His | p.R483H | Q96NY9 | protein_coding | tolerated(0.28) | benign(0) | TCGA-AY-6197-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |